Conversion at Maturity. If the Notes have not been previously converted prior to the Maturity Date (as such term is defined in the Notes), upon the written election of the Purchaser Majority the entire unpaid principal amount and unpaid accrued interest (if any) of each Note shall be automatically converted into that number of shares of the Company’s Series C-2 Preferred equal to the quotient of (i) the outstanding principal amount plus unpaid accrued interest (if any) divided by (ii) the Series C-2 Original Issue Price.
Appears in 2 contracts
Sources: Convertible Note and Warrant Purchase Agreement (Hyperion Therapeutics Inc), Convertible Note and Warrant Purchase Agreement (Hyperion Therapeutics Inc)
Conversion at Maturity. If the Notes have not been previously converted prior to the Maturity Date (as such term is defined in the Notes), upon the written election of the Purchaser Majority the entire unpaid principal amount and unpaid accrued interest (if any) of each Note shall be automatically converted into that number of shares of the Company’s Series C-2 B-1 Preferred Stock equal to the quotient of (ia) the outstanding principal amount plus unpaid accrued interest (if any) divided by (iib) the Series C-2 Original Issue B-1 Preferred Stock Conversion Price.
Appears in 1 contract
Sources: Convertible Note Purchase Agreement (Syndax Pharmaceuticals Inc)